About Arvelle Therapeutics
Arvelle Therapeutics is a company based in Zug (Switzerland) founded in 2019 was acquired by Angelini Pharma in January 2021. Arvelle Therapeutics has raised $222.7 million across 2 funding rounds from investors including Angelini Pharma, Andera Partners and Life Sciences Partners. Arvelle Therapeutics operates in a competitive market with competitors including Marinus Pharma, ORPHELIA Pharma, EpilepsyGTx, Corlieve Therapeutics and Epygenix, among others.
- Headquarter Zug, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$222.7 M (USD)
in 2 rounds
-
Latest Funding Round
$42.7 M (USD), Series A
May 26, 2020
-
Investors
Angelini Pharma
& 8 more
-
Employee Count
Not available
-
Acquired by
Angelini Pharma
(Jan 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Arvelle Therapeutics
Arvelle Therapeutics has successfully raised a total of $222.7M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $42.7 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arvelle Therapeutics
Arvelle Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Angelini Pharma, Andera Partners and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm focused on life science and healthcare companies
|
Locked | Locked | Locked | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Arvelle Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arvelle Therapeutics
Investment portfolio details for Arvelle Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arvelle Therapeutics
Detailed financials for Arvelle Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arvelle Therapeutics Comparisons
Peer comparison for Arvelle Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arvelle Therapeutics
Arvelle Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Marinus Pharma, ORPHELIA Pharma, EpilepsyGTx, Corlieve Therapeutics and Epygenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics to treat seizure disorders
|
|
| Locked | Locked | Locked |
Therapies for pediatric neurology, oncology, and hematology are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for focal refractory epilepsy are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for neurological disorders are developed using AAV gene delivery.
|
|
| Locked | Locked | Locked |
Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions.
|
Detailed competitors of Arvelle Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arvelle Therapeutics
Complete news archive for Arvelle Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arvelle Therapeutics
Arvelle Therapeutics was founded in 2019.
Arvelle Therapeutics is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
Arvelle Therapeutics is a funded company, having raised a total of $222.7M across 2 funding rounds to date.
Arvelle Therapeutics was founded in 2019 in Zug, Switzerland. Small molecule therapies for central nervous system disorders are developed by the firm. The lead candidate, Cenobamate, is targeted at partial-onset seizures in adult patients via GABA-A receptor modulation and sodium current inhibition. Exclusive rights for European development and commercialization were acquired from SK Biopharmaceuticals. An NDA for Cenobamate was filed in February 2019.
Arvelle Therapeutics's top competitors include Marinus Pharma, ORPHELIA Pharma and Corlieve Therapeutics.
Arvelle Therapeutics has 9 investors. Key investors include Angelini Pharma, Andera Partners, Life Sciences Partners, KB Investment, and Sio Gene Therapies.